FindTrial
Sign In

A clinical trial to study the effects of Memantine on improving mental functions and memory in patients with seizure disease

Evaluating the efficacy of Memantine on improving Cognitive Functions in Epileptic Patients receiving Anti-Epileptic Drugs: A double blind placebo controlled clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/04/003573
Enrollment
60
Registered
2013-04-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Epilepsy patients receiving anti epileptic drugs with mild to moderate cognitive impairment

Interventions

Intervention1: Memantine hydrochloride: Memantine hydrochloride tablet 5 mg once daily oral for 8 weeks and dose is titrated to 10 mg once daily oral for next 8 weeks.Duration of intervention is 4 mon

Sponsors

SRM University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Epileptic patients of Age > 18 years and 2. Seizure frequency of less than four per month 3.Patients willing to give informed consent

Exclusion criteria

Exclusion criteria: 1.Age 55 years 2.Interictal period (2 weeks), More than 4 attacks per month 3.Mental Retardation 4.Family H/O Psychiatric disorders 5.Progressive neurologic disease 6.Severe medical illness including renal insufficiency 7.Pregnant or lactating women

Design outcomes

Primary

MeasureTime frame
1.Improvement in Cognitive functions 2.Improvement in MemoryTimepoint: 0,1,2,3 and 4 months—

Secondary

MeasureTime frame
1.Improvement in Quality of Life 2.Improvement in self reported memory functionsTimepoint: 0,1,2,3 and 4 months—

Countries

India

Contacts

Public ContactProf Dr Sathya Narayanan V

SRM Medical College SRM University

satya672000@gmail.com9384633405

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 12, 2026